Study offers clues to precision treatments for lukemia
-
Clues to precision treatments for a tough childhood leukemia
Researchers reveal genetic secrets of a high-risk pediatric leukemia called Ph-ALL, and find treatment potential in the drug ruxolitinib.
-
A promising anti-inflammatory drug tames the immune system
The drug ruxolitinib shows promise in targeting inflammatory reactions in the immune disorder hemophagocytic lymphohistiocytosis (HLH).
-
Parental influence extends to drug response
Researchers demonstrate how differences in inherited genetic makeup can cause problems during leukemia treatment.
-
Understanding how brain tumor treatment affects the brain
An unprecedented study finds that survivors of childhood brain tumors are at risk of memory and intelligence deficits. A key goal? Catch them early.
From Promise, Spring 2016
More articles from this issue
-
St. Jude Proton Therapy: Think Positive
St. Jude opens the first proton therapy center designed just for children.
-
Going Global: Taking St. Jude to the World
St. Jude expands its mission to the most remote parts of the globe.
-
Tyler's Treehouse
A little boy's legacy may help save the lives of kids with a rare brain tumor.
-
Accelerating Progress Through Global Collaboration
St. Jude prepares to greatly increase the number of children treated on clinical trials such as SJMB12.
-
ProteinPaint: Making Data Beautiful
An elegant Web tool developed at St. Jude makes it easy for any scientist to explore cancer genome data.
-
St. Jude Tells Malaria to Buzz Off
Scientists and clinicians team up to create a potential malaria drug that could save untold lives worldwide.
-
The Perfect Gift
Donate your birthday to help St. Jude kids.
-
Science Students Come to St. Jude
Memphis-area high school students and teachers visit St. Jude to get an exclusive look at science in progress.